Bankruptcy: Kiromic Biopharma, Inc.

Form Type: 8-K

Filing Date: 2025-03-21

Corporate Action: Bankruptcy

Type: New

Accession Number: 000143774925008671

Filing Summary: On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for relief under Chapter 7 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. This filing leads to the appointment of a Chapter 7 trustee, who will manage the bankruptcy estate and may liquidate the company's assets. The initial hearing for creditors will be arranged and notices will be distributed. Additionally, effective the same day, four members of the Board of Directors resigned—Pietro Bersani, Michael Nagel, Mike Catlin, and Pamela Misajon—due to the bankruptcy filing, which renders the board powerless. The company had also terminated key executives including Chief Financial Officer Brian Hungerford, Chief Operating Officer Leonardo Mirandola, and Chief of Staff Scott Dahlbeck as of March 21, 2025.

Document Link: View Document